CSL Behring to become latest partner in BaseLaunch Phase II
BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that CSL … Continue reading “CSL Behring to become latest partner in BaseLaunch Phase II”
BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that CSL … Continue reading “CSL Behring to become latest partner in BaseLaunch Phase II”
Josep Tabernero joins SAB and Julian Blagg elevated to SAB Chair Martin … Continue reading “NeoPhore Strengthens Scientific Leadership Team”
20 Years’ Industry Experience Managing Biotech Companies in US and Europe Aim … Continue reading “NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer”
EUR23M Series A Financing to Advance Lead Novel Llama-derived Antibody into Clinical … Continue reading “ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19”
Fund+ strengthens portfolio with medical device company developing a novel ‘invisible’ sensor … Continue reading “Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV”
Sydney, Australia and Los Angeles, California 21 July 2020 – Clarity Pharmaceuticals, … Continue reading “Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets”
The Optimum team is very proud to be recognised for our work … Continue reading “Optimum recognised for its work in the M&A PR advisor league tables”
LONDON and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription”
BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that … Continue reading “Bridge Biotherapeutics becomes BaseLaunch’s first Asia Pacific partner”
Reapplix announces that it has successfully received Medicare reimbursement coding instructions from … Continue reading “Reapplix receives new reimbursement coding and completes USD 22.6M equity financing to drive US commercialisation”
3B Future Health Fund Joins Blue Chip Investor Syndicate Accelerate Development of … Continue reading “iOnctura Extends Series A to EUR 20.1M”
Life sciences focused fund also announces first close of EUR76 million July … Continue reading “New Nordic Life Science Venture Fund, Eir Ventures, launched to leverage the untapped potential of Health Care Innovation”
We are proud to announce that BB Pureos Bioventures has become a … Continue reading “BB Pureos Bioventures has become a partner in BaseLaunch Phase II”
Amsterdam, The Netherlands, July 8, 2020 – Kiadis Pharma N.V. (“Kiadis” or … Continue reading “Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties”
Oversubscribed funding round to advance the development of investigational, first-in-class antibody-drug conjugates … Continue reading “VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology”
Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused … Continue reading “Verona Pharma plc: Issue of Equity and Total Voting Rights”
Primes the immune system to attack cancer cells in HPV16-positive cancers ISA … Continue reading “ISA Pharmaceuticals Receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer”
24 June 2020 We welcome back Roivant Sciences with open arms for … Continue reading “Roivant Sciences continues its partnership with BaseLaunch for phase II”
23 June 2020, Cambridge, UK: STORM Therapeutics, the leading biotechnology company focused … Continue reading “STORM Therapeutics appoints Dr. Josefin-Beate Holz as Chief Medical Officer”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com